Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access
Companies’ work part of a long-term commitment to diversifying clinical trials and expanding access to precision diagnostics globally PALO ALTO, Calif. & ACCRA, Ghana--(BUSINESS WIRE)--#liquidbiopsy--Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced…
Source: newsghana.com.gh